Document:

omer_Ex10_1

		
			NINTH AMENDMENT TO LEASE
		

		
			THIS NINTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 15th day of January, 2020 (the “Ninth Amendment Execution Date”),  by and between BMR-201 ELLIOTT AVENUE LLC, a Delaware limited liability company  (“Landlord”), and OMEROS CORPORATION, a Washington corporation  (“Tenant”).  
		

		
			RECITALS
		

			
	
			
				 A.
			WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of January 27, 2012 (the “Original Lease”),  as amended by that certain First Amendment to Lease dated as of November 5, 2012, that certain Second Amendment to Lease dated as of November 16, 2012 (the “Second Amendment”), that certain Third Amendment to Lease dated as of October 16, 2013, that certain Fourth Amendment to Lease dated as of September 8, 2015,  that certain Fifth Amendment to Lease dated as of September 1, 2016, that certain Sixth Amendment to Lease dated as of October 18, 2018, that certain Seventh Amendment to Lease dated as of April 15, 2019 and that certain Eighth Amendment to Lease dated as of October 28, 2019 (collectively, and as the same may have been further amended, amended and restated, supplemented or modified from time to time, the “Existing Lease”), whereby Tenant leases certain premises (the “Existing Premises”) from Landlord at 201 Elliott Avenue West in Seattle, Washington (the “Building”), including certain space within the Building’s vivarium (such portion of the Building’s vivarium currently leased to Tenant, the “Tenant’s Existing Vivarium Space”), which excludes the Additional Vivarium Premises comprising approximately 5,177 square feet of Rentable Area that Tenant leased from Landlord pursuant to the Second Amendment, with respect to which Tenant exercised its right to terminate pursuant to that certain letter dated December 17, 2015 from Tenant to Landlord;

			
	
			
				 B.
			WHEREAS, Tenant desires to lease additional premises from Landlord in the Building’s vivarium; and

			
	
			
				 C.
			WHEREAS, Landlord and Tenant desire to modify and amend the Existing Lease only in the respects and on the conditions hereinafter stated.

		
			AGREEMENT
		

		
			NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as follows:
		

			
	
			
				 1.
			Definitions.  For purposes of this Amendment, capitalized terms shall have the meanings ascribed to them in the Existing Lease unless otherwise defined herein.  The Existing Lease, as amended by this Amendment, is referred to collectively herein as the “Lease.” From and after the date hereof, the term “Lease,” as used in the Existing Lease, shall mean the Existing Lease, as amended by this Amendment.

			
	
			
				 2.
			Sixth Additional Vivarium Premises.  Effective as of the Ninth Amendment Execution Date, Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, approximately one thousand one hundred forty-one  (1,141)  aggregate additional square feet of 

		 

	Rentable Area located collectively in Rooms 158 and 155A of the Vivarium, as shown on Exhibit A attached hereto (collectively, the “Sixth Additional Vivarium Premises”), for use by Tenant in accordance with the Permitted Use and in accordance with all other terms and conditions of the Lease.  From and after the Ninth Amendment Execution Date, the term “Premises,” as used in the Lease shall mean the Existing Premises plus the Sixth Additional Vivarium Premises, and the term “Tenant’s Vivarium Space,” as used in the Lease, shall mean the Tenant’s Existing Vivarium Space plus the Sixth Additional Vivarium Premises. 

			
	
			
				 3.
			Sixth Additional Vivarium Term.    The Term of the Lease with respect to the Sixth Additional Vivarium Premises (as the same may be earlier terminated in accordance with the Lease, the “Sixth Additional Vivarium Term”) shall commence on the Ninth Amendment Execution Date and shall expire on the Term Expiration Date.  Failure by Tenant to obtain validation by any medical review board or other similar governmental licensing of the Sixth Additional Vivarium Premises required for the Permitted Use by Tenant shall not serve to extend the commencement of the Sixth Additional Vivarium Term.

			
	
			
				 4.
			Condition of Sixth Additional Vivarium Premises.    Tenant acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty with respect to the condition of the Sixth Additional Vivarium Premises or with respect to the suitability of the Sixth Additional Vivarium Premises for the conduct of Tenant’s business.  Tenant acknowledges that (a) it is fully familiar with the condition of the Sixth Additional Vivarium Premises and agrees to take the same in its condition “as is” as of the Ninth Amendment Execution Date and (b) Landlord shall have no obligation to alter, repair or otherwise prepare the Sixth Additional Vivarium Premises for Tenant’s occupancy or to pay for or construct any improvements to the Sixth Additional Vivarium Premises.  Tenant’s taking of possession of the Sixth Additional Vivarium Premises shall, except as otherwise agreed to in writing by Landlord and Tenant, conclusively establish that the Sixth Additional Vivarium Premises were at such time in good, sanitary and satisfactory condition and repair.

			
	
			
				 5.
			Base Rent and Additional Rent.  In addition to all Base Rent for the Existing Premises, commencing on the Ninth Amendment Execution Date and continuing for the duration of the Sixth Additional Vivarium Term, Tenant shall pay to Landlord (in accordance with the provisions of the Lease) Base Rent for the Sixth Additional Vivarium Premises.  Base Rent (including the monthly and annual installments of Base Rent) for the Sixth Additional Vivarium Premises shall equal the applicable amounts set forth on Exhibit B attached hereto.    In addition to all Additional Rent for the Existing Premises, commencing as of the Ninth Amendment Execution Date and continuing for the duration of the Sixth Additional Vivarium Term, Tenant shall pay to Landlord Additional Rent (as defined in (and in accordance with the provisions of) the Lease) with respect to the Sixth Additional Vivarium Premises.

			
	
			
				 6.
			Pro Rata Share.  Tenant’s Pro Rata Share of the Project with respect to the Sixth Additional Vivarium Premises shall be 0.75%.  Therefore, commencing as of the Ninth Amendment Execution Date, Tenant’s Pro Rata Share of the Project for the entire Premises (i.e., the Existing Premises plus the Ninth Amendment Vivarium Premises) shall be 73.60%.

		
			

		 

		

			2

		

		

			
	
			
				 7.
			Termination Option.    Notwithstanding anything to the contrary in the Lease, Tenant shall have the right to terminate the Lease, but only with respect to the Sixth Additional Vivarium Premises (and no less than all of the Sixth Additional Vivarium Premises), by providing written notice (the “Sixth Additional Vivarium Termination Notice”) to Landlord at least sixty (60) days prior to Tenant’s desired termination date (the “Sixth Additional Vivarium Termination Date”), which Sixth Additional Vivarium Termination Date shall be set forth in the Sixth Additional Vivarium Termination Notice.  Subject to (a) Landlord’s timely receipt of the Sixth Additional Vivarium Termination Notice and (b) Tenant surrendering the Sixth Additional Vivarium Premises in the condition required under the Lease (including, without limitation, Section 18.2 and Article 26 of the Lease), then, as of the Sixth Additional Vivarium Termination Date, the Lease with respect to the Sixth Additional Vivarium Premises only shall terminate and be of no further force or effect, and Landlord and Tenant shall be relieved of their respective obligations under the Lease with respect to the Sixth Additional Vivarium Premises only from and after the Sixth Additional Vivarium Termination Date, except with respect to those obligations set forth in the Lease that expressly survive the expiration or earlier termination thereof, including payment by Tenant of all amounts owed by Tenant pursuant to the Lease with respect to the Sixth Additional Vivarium Premises for the period up to and including the Sixth Additional Vivarium Termination Date.  The termination right granted to Tenant pursuant to this Section shall automatically terminate and be of no further force or effect in the event that (y) Tenant assigns, subleases or otherwise Transfers the Sixth Additional Vivarium Premises or any portion thereof to other entities or persons, other than in connection with an Exempt Transfer (or in connection with any sublease approved by Landlord pursuant to Article 29 of the Lease), or (z) Tenant’s right to possession of the Sixth Additional Vivarium Premises has previously been terminated.  The termination right granted to Tenant pursuant to this Section is personal to Omeros Corporation, a Washington corporation (“Omeros”) and any Permitted Transferees of Omeros, and may not be exercised by any other assignee, sublessee or transferee of Tenant’s or a Permitted Transferee’s interest in the Lease.

			
	
			
				 8.
			Broker. Tenant represents and warrants that it has not dealt with any broker or agent in the negotiation for or the obtaining of this Amendment and agrees to reimburse, indemnify, save, defend (at Landlord’s option and with counsel reasonably acceptable to Landlord, at Tenant’s sole cost and expense) and hold harmless the Landlord Indemnitees for, from and against any and all cost or liability for compensation claimed by any such broker or agent employed or engaged by it or claiming to have been employed or engaged by it.

			
	
			
				 9.
			No Default.  Tenant represents, warrants and covenants that, to the best of Tenant’s knowledge, Landlord and Tenant are not in default of any of their respective obligations under the Existing Lease and no event has occurred that, with the passage of time or the giving of notice  (or both) would constitute a default by either Landlord or Tenant thereunder.

			
	
			
				 10.
			Effect of Amendment.  Except as modified by this Amendment, the Existing Lease and all the covenants, agreements, terms, provisions and conditions thereof shall remain in full force and effect and are hereby ratified and affirmed.  In the event of any conflict between the terms contained in this Amendment and the Existing Lease, the terms herein contained shall supersede and control the obligations and liabilities of the parties.

		
			

		 

		

			3

		

		

			
	
			
				 11.
			Successors and Assigns.  Each of the covenants, conditions and agreements contained in this Amendment shall inure to the benefit of and shall apply to and be binding upon the parties hereto and their respective heirs, legatees, devisees, executors, administrators and permitted successors and assigns and sublessees.  Nothing in this section shall in any way alter the provisions of the Lease restricting assignment or subletting.

			
	
			
				 12.
			Miscellaneous.  This Amendment becomes effective only upon execution and delivery hereof by Landlord and Tenant. The captions of the paragraphs and subparagraphs in this Amendment are inserted and included solely for convenience and shall not be considered or given any effect in construing the provisions hereof.  All exhibits hereto are incorporated herein by reference.    Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for a lease, and shall not be effective as a lease, lease amendment or otherwise until execution by and delivery to both Landlord and Tenant.

			
	
			
				 13.
			Authority.  Tenant guarantees, warrants and represents that the individual or individuals signing this Amendment have the power, authority and legal capacity to sign this Amendment on behalf of and to bind all entities, corporations, partnerships, limited liability companies, joint venturers or other organizations and entities on whose behalf such individual or individuals have signed.

			
	
			
				 14.
			Counterparts; Facsimile and PDF Signatures.  This Amendment may be executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document.    A facsimile or portable document format (PDF) signature on this Amendment shall be equivalent to, and have the same force and effect as, an original signature.

		
			[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]
		

		
			 
		

		
			 
		

		
			

		 

		

			4

		

		

		
			IN WITNESS WHEREOF, Landlord and Tenant have executed this Amendment as of the date and year first above written.
		

		
			LANDLORD:
		

		
			BMR-201 ELLIOTT AVENUE LLC,
		

		
			a  Delaware limited liability company
		

			
					
						 

					
					
						 

				
	
					
						By:

					
					
						/s/ KEVIN M. SIMONSEN

				
	
					
						Name:

					
					
						Kevin M. Simonsen

				
	
					
						Title:

					
					
						EVP, General Counsel & Secretary

				

		
			TENANT:
		

		
			OMEROS CORPORATION,
		

		
			a  Washington corporation
		

			
					
						 

					
					
						 

				
	
					
						By:

					
					
						/s/ GREGORY A. DEMOPULOS, M.D.

				
	
					
						Name:

					
					
						Gregory A. Demopulos, M.D.

				
	
					
						Title:

					
					
						Chairman and Chief Executive Officer

				

		
			 
		

		
			
		

		
			

		 

		

			 

		

		

		
			EXHIBIT A
		

		
			SIXTH ADDITIONAL VIVARIUM PREMISES
		

		
			**The cross-hatched area above represents the Sixth Additional Vivarium Premises.  Landlord makes no representation or warranty with respect any items depicted in this Exhibit A (including, without limitation, any furniture, fixtures or equipment), including whether any such items currently exist within the Building or the Project.
		

		
			
		

		
			

		 

		

			 

		

		

		
			EXHIBIT B
		

		
			BASE RENT FOR SIXTH ADDITIONAL VIVARIUM PREMISES
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Dates

					
					
						Square Feet of Rentable Area

					
					
						Annual Base Rent per Square Foot Of Rentable Area

					
					
						Monthly Base Rent

				
	
					
						Ninth Amendment 
Executed Date - 
November 15, 2019

					
					
						1,141

					
					
						$71.64

					
					
						$6,811.77

				
	
					
						November 16, 2019-
November 15, 2020

					
					
						1,141

					
					
						$73.79

					
					
						$7,016.20

				
	
					
						November 16, 2020-
November 15, 2021

					
					
						1,141

					
					
						$76.01

					
					
						$7,227.28

				
	
					
						November 16, 2021-
November 15, 2022

					
					
						1,141

					
					
						$78.29

					
					
						$7,444.07

				
	
					
						November 16, 2022-
November 15, 2023

					
					
						1,141

					
					
						$80.63

					
					
						$7,666.57

				
	
					
						November 16, 2023-
November 15, 2024

					
					
						1,141

					
					
						$83.05

					
					
						$7,896.67

				
	
					
						November 16, 2024-
November 15, 2025

					
					
						1,141

					
					
						$85.55

					
					
						$8,134.38

				
	
					
						November 16, 2025-
November 15, 2026

					
					
						1,141

					
					
						$88.11

					
					
						$8,377.79

				
	
					
						November 16, 2026-
November 15, 2027

					
					
						1,141

					
					
						$90.76

					
					
						$8,629.76omer_Ex10_2

		
			OMEROS CORPORATION
		

		
			CONSULTING AGREEMENT
		

		
			 
		

		
			This Consulting Agreement (the “Agreement”) is entered into by and between Omeros Corporation (“Omeros”) and Kurt Zumwalt (the “Consultant”) as of February 10, 2020
		

		
			 
		

			
	
			
				 1.
			

			
	
			
			Consulting Services.  Consultant will provide consulting services (the “Services”) to Omeros as described in the attached Exhibit A or as may otherwise be mutually agreed in writing.  Consultant will use his best efforts to perform the Services in a manner satisfactory to Omeros, in a reasonable manner consistent with the professional standards generally applicable to such Services and will perform the Services in accordance with  (i) all applicable Omeros corporate and compliance policies and procedures and (ii) all applicable laws and state and federal regulations. With respect to the Services, Consultant will report to the Chief Executive Officer (“CEO”) or other individual designated by the CEO.

		
			 
		

			
	
			
				 2.
			

			
	
			
			Compensation.  As full and complete consideration for the Services described in Exhibit A and all other of Consultant’s obligations under this Agreement, Omeros will compensate Consultant as also described in Exhibit A.

		
			 
		

			
	
			
				 3.
			

			
	
			
			Term.  Consultant will serve as a consultant to Omeros for an initial term commencing on  the date hereof (the “Effective Date”) and continuing until an ending date agreed to in writing or by mutual course of conduct (the “Term”).  Consultant’s obligations with respect to Confidentiality, Intellectual Property and Use of Names set forth below will survive termination of this Agreement.

		
			 
		

			
	
			
				 4.
			

			
	
			
			Independent Contractor.  Consultant is an independent contractor, and not an employee of Omeros.  Consultant is not eligible for any employee benefits.  Consultant, and not Omeros, is responsible for payment of all of Consultant’s taxes and for any workers compensation or disability insurance as may be required by law.  Consultant is not authorized to enter into any contracts or obligations that bind Omeros without the prior written authorization of Omeros.  

		
			 
		

			
	
			
				 5.
			

			
	
			
			Confidentiality    

			
	
			
				 5.1.
			

			
	
			
			As used in this Agreement, “Omeros Technology”  means the following technologies that have been developed or are owned and/or held by Omeros:  (a) methods and pharmaceuticals or other agents to inhibit pain and inflammation and/or smooth muscle spasm,  and/or to promote mydriasis, for use in surgical procedures (including without limitation arthroscopic, urologic, ophthalmologic and general surgical procedures); (b) methods, antibodies and other agents and compositions for the inhibition of the complement immune system; (c) G-Protein coupled receptor (GPCR) therapeutic targets, expression profiles, assay methods for screening compounds for activity at GPCR targets, GPCR agonists and antagonists and therapeutic methods and compositions targeting GPCRs including, but not limited to, the treatment of cancer, pain, sleep disorders, obesity, neuromuscular and neuropsychiatric disorders; (d) agents, compositions and therapeutic methods targeting phosphodiesterases including, but not limited to, the 

		 

		

			1

		

		

			 

		

	treatment of neuromuscular, neurodegenerative,  neuropsychiatric, motor, cognitive and inflammatory disorders and the treatment and prevention of addiction and compulsive disorders; (e) genetically engineered knock-out and knock-in mice, inducible knock-out mice and methods for generating the same; (f) agents, compositions and therapeutic methods for treating addiction and/or preventing addiction to addictive agents; (g) methods and libraries for generating antibodies using targeted gene replacement and antibodies generated therefrom; (h)  agents, compositions and therapeutic methods targeting proteinases, including, but not limited to, use as antifibrinolytics; and (i) any other business or scientific area in which Consultant becomes aware that Omeros is active or has commenced planning or preparation for activity.

		
			 
		

			
	
			
				 5.2.
			

			
	
			
			As used in this Agreement, “Confidential Information” means all information or materials which relate to the Omeros Technology that are made available to Consultant by Omeros at any time, or which Consultant obtains or develops under this Agreement, including without limitation, research and development information, know-how, inventions, technical data, knock-out and knock-in mouse strains, gene expression profiles, behavioral and physiological assays, phenotypes, cell lines, cellular, biochemical and chemical assays, chemical structure-activity relationships, sequences, formulae, treatment methods, clinical trial design criteria, protocols, case report forms, patient data, investigators’ brochures, processes, chemistry, manufacturing and controls information, regulatory information, product development information, business or marketing plans or strategies, financial and investor information, customer lists or information and any data concerning the existing business or reasonably foreseeable future business of Omeros, as well as all other information which Consultant should reasonably know is not generally available to the public.

		
			 
		

			
	
			
				 5.3.
			

			
	
			
			During the Term of this Agreement and at least five years afterward, Consultant shall not at any time, without the written authorization of Omeros’ CEO, disclose or otherwise make known or available to any person, firm, corporation or other entity other than Omeros, or use for any purpose other than performance of this Agreement, any Confidential Information.  Consultant shall utilize reasonable procedures to safeguard Confidential Information, including releasing Confidential Information only to employees or associates on a “need-to-know” basis, after first obtaining a written agreement from such individuals to abide by the same duties of confidentiality, non-use and Intellectual Property as are required of Consultant.  Consultant shall not attempt to analyze or reproduce through reverse engineering any product or composition included within the Confidential Information, except as may be authorized and necessary to perform this Agreement.  When requested by Omeros, Consultant will immediately return to Omeros all Confidential Information and all copies thereof in Consultant’s possession or control. Notwithstanding the foregoing, the provisions hereof shall not be interpreted to prevent Consultant from reporting potential violations of federal law or regulation to governmental regulators or making other disclosures that are protected under the whistleblower provisions of federal law or regulation.

		
			 
		

			
	
			
				 5.4.
			

			
	
			
			These obligations of confidentiality and non-use do not apply to information that Consultant can establish using written documentation: (a) is or becomes generally 

		 

		

			2

		

		

			 

		

	available to the public other than as a result of a disclosure by Consultant; (b) was in the possession of Consultant prior to its being furnished to Consultant directly or indirectly from Omeros; or (c) becomes available to Consultant on a non-confidential basis from a source other than Omeros, which source is not bound by an obligation of confidentiality to Omeros or any other party with respect to such information.

		
			 
		

			
	
			
				 6.
			

			
	
			
			Intellectual Property  

			
	
			
				 6.1.
			

			
	
			
			The term “Omeros Intellectual Property” means all patents, trademarks, copyrights, trade secrets, other intellectual property rights, inventions, discoveries, ideas, compositions, conceptions, processes, developments, designs, business plans, trade secrets, know-how, products, data, programs, processes, methods, protocols and written or electronic writings, illustrations, images or other tangible expressions that: (a) are owned or held by Omeros prior to this Agreement or are created, developed, conceived, reduced to practice, obtained or improved independently of Consultant; or (b) relate to the Omeros Technology and (i) are created, developed, conceived, reduced to practice, obtained or improved by Consultant solely or jointly with others during the course of providing the Services or (ii) result from any use by Consultant of Omeros Confidential Information, premises, equipment or property (tangible or intangible).  

		
			 
		

			
	
			
				 6.2.
			

			
	
			
			Consultant agrees to disclose to Omeros, fully and promptly in writing, all Omeros Intellectual Property developed by Consultant that arises under this Agreement. 

		
			 
		

			
	
			
				 6.3.
			

			
	
			
			All work product produced by Consultant during the performance of the Services and all Omeros Intellectual Property is the sole property of Omeros, and to the fullest extent permitted by law will be deemed “works made for hire”.  Consultant hereby assigns and transfers to Omeros, for no additional compensation, any and all right and title to and interest in Omeros Intellectual Property that Consultant may have or acquire, including any copyrights and registrations and renewals therefore, any inventions, any United States, International and foreign patent applications filed on such inventions, and the right to apply for all such patent applications in Consultant’s name or in the name of Omeros. 

		
			 
		

			
	
			
				 6.4.
			

			
	
			
			Consultant agrees to execute all documents and provide all other requested assistance to Omeros to permit Omeros to confirm title, obtain, protect and enforce all Omeros Intellectual Property.  Consultant will be compensated only for Consultant’s time spent in rendering such assistance on a reasonable basis.

		
			 
		

			
	
			
				 6.5.
			

			
	
			
			Consultant agrees that Omeros will have a non-exclusive, fully paid, transferable license to use for all purposes anywhere in the world any of Consultant’s intellectual property incorporated by Consultant within the Omeros Intellectual Property.

		
			 
		

			
	
			
				 7.
			

			
	
			
			Conflicts with this Agreement.    

			
	
			
				 7.1.
			

			
	
			
			Consultant warrants that, to the best of Consultant’s knowledge, nothing that Consultant will do for, or provide, use or disclose to, Omeros in the course of providing the Services under this Agreement conflicts with any obligation to or rights of third parties.

		
			 
		

		
			

		 

		

			3

		

		

			 

		

		

			
	
			
				 7.2.
			

			
	
			
			Consultant shall notify Omeros’ CEO or other individual designated by the CEO if, during the Term of this Agreement, Consultant undertakes or is subject to a consulting or employment relationship or other obligation with a third party that is engaged in a business enterprise that is directly competitive with any portion of the Omeros Technology.

		
			 
		

			
	
			
				 8.
			

			
	
			
			Miscellaneous.

			
	
			
				 8.1.
			

			
	
			
			Integration.  Any term of this Agreement may be amended or waived only with the written consent of the parties. 

		
			 
		

			
	
			
				 8.2.
			

			
	
			
			Severability.  If one or more provisions of this Agreement are held to be unenforceable under applicable law, then such provision will be excluded from this Agreement, and the balance of the Agreement will be interpreted and enforceable as if such provision were so excluded. 

		
			 
		

			
	
			
				 8.3.
			

			
	
			
			Interpretation.  The laws of the State of Washington will govern the validity, interpretation, construction and performance of this Agreement, without giving effect to the principles of conflict of laws.  In the event of a breach of any obligation under this Agreement, the parties may apply to any court of competent jurisdiction for preliminary or interim equitable relief.

		
			 
		

			
	
			
				 8.4.
			

			
	
			
			Assignment.  This Agreement will be binding on Consultant’s agents and representatives, and will inure to the benefit of Omeros’ assigns or successors in interest.  Consultant may not assign this Agreement and may not subcontract any of Consultant’s obligations under this Agreement, without the express prior written consent of Omeros. 

		
			 
		

			
	
			
				 8.5.
			

			
	
			
			Advice of Counsel.  Consultant acknowledges that Omeros has recommended that Consultant seek independent legal counsel to review this Agreement, and that Consultant has read and understood all of the terms and provisions of this Agreement. 

		
			 
		

			
	
			
				 8.6.
			

			
	
			
			Counterparts.  This Agreement may be executed in one or more counterparts, all of which together shall constitute one and the same agreement.

		
			 
		

		
			 
		

		
			[Signature Page Follows]
		

		
			

		 

		

			4

		

		

			 

		

		

		
			The parties have executed this Consulting Agreement on the date first set forth above.
		

		
			 
		

		
			 
		

			
					
						 

					
					
						 

				
	
					
						OMEROS CORPORATION

				
	
					
						 

					
					
						 

				
	
					
						By:

					
					
						/s/ GREGORY A. DEMOPULOS, M.D.

				
	
					
						 

					
					
						Gregory A. Demopulos, M.D.

				
	
					
						 

					
					
						Chairman and Chief Executive Officer

				

		
			 
		

		
			Address:  201 Elliott Avenue West
		

		
			                Seattle, Washington 98119
		

		
			 
		

		
			 
		

			
					
						 

					
					
						 

				
	
					
						KURT ZUMWALT

				
	
					
						 

					
					
						 

				
	
					
						/s/ KURT ZUMWALT

				
	
					
						Signature

				

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			 

		

		

			 

		

		

		
			Exhibit A
		

		
			 
		

		
			OMEROS CORPORATION 
		

		
			CONSULTING AGREEMENT 
		

		
			 
		

		
			This Exhibit A shall set forth a description of the consulting services and compensation to be paid to the Consultant pursuant to the Consulting Agreement.  Capitalized terms used in this Exhibit A and not defined herein will have the meaning given such terms in the Director Consulting Agreement.
		

		
			 
		

			
	
			
				 1.
			

			
	
			
			Description of the Consulting Services.

		
			1.2Consultant will provide advisory services and tactical implementation of business and financial strategies that further the Company’s corporate goals and priorities including,  without limitation, securing and further developing the Company’s business relationships with major banks and financial institutions. 
		

		
			 
		

			
	
			
				 2.
			

			
	
			
			Compensation.

		
			2.1Consulting Compensation.  On the Effective Date, the Consultant will be granted a “Nonstatutory Stock Options” (as defined in the Omeros Corporation 2017 Omnibus Incentive Compensation Plan (as amended and restated effective as of June 7, 2019) (the “Plan”))  to purchase an aggregate of 11,750 shares of Omeros’ common stock, par value $0.01 per share, at a purchase price equal to the fair market value (as determined by the Board of Directors) on the date of the grant (the “Consulting Award”).  Subject to Section 13 of the Plan, the Consulting Award will vest and become exercisable as to 1/12 of the total shares subject to the Consulting Award each month following the date of grant, provided that the Consultant continues to be a Service Provider (as defined in the Plan) through each such date.  The term of the Consulting Award will be 10 years.  The Consulting Award will subject to the terms of the Plan in all respects.
		

		
			 
		

		
			2.2Compensation for Board Service.  For the avoidance of doubt, in addition to the compensation set forth in Section 2.1 of this Exhibit A the Consultant shall be entitled to receive compensation in connection with his service as a director of Omeros in the same manner set forth with respect to “Outside Directors” (as defined therein) of the Omeros Corporation Non-Employee Director Compensation Policy, effective as of January 1, 2017, as it may be amended from time to time.
		

		
			 
		

		
			2.3Indemnification.   Omeros and the Consultant shall enter into an Indemnification Agreement providing for indemnification of the Consultant in his capacity as a director, to the maximum extent permissible under applicable law, such Indemnification Agreement to be in substantially the form provided to Omeros’ other non-employee directors.
		

		
			 
		

		
			2.4Expense Reimbursement.  Consultant is not authorized to incur any expenses on behalf of Omeros, without the prior written authorization of Omeros’ CEO or other individual designated by the CEO.  Consultant will be entitled to reimbursement for reasonable expenses (including reasonable travel expenses) incurred by Consultant, which expenses 

		 

		

			A-1

		

		

			 

		

are (a) necessary for and directly arise from the performance of the Services and (b) have been pre-approved in writing by Omeros’ CEO or other individual designated by the CEO, not including any indirect expenses, overhead or expenses that will be reimbursed by third parties.  Notwithstanding the foregoing, the Consultant may incur and be reimbursed for his reasonable and documented expenses in connection with his service on Omeros’ Board of Directors, such as to attend meetings of Omeros’ Board of Directors, without the prior written authorization of Omeros’ CEO in the same manner and to the same extent as Omeros’ non-employee directors generally. Additionally, Omeros will reimburse Consultant’s reasonable and documented legal fees incurred in connection with the review and execution of the Consulting Agreement, not to exceed $10,000.
		

		
			 
		

		
			2.5Other.  During the term of his service on Omeros’ Board of Directors, the Consultant shall be entitled to receive cash and equity compensation, expense reimbursement and other benefits related to service on the Board of Directors in the same manner and to the same extent as Omeros’ non-employee directors generally.
		

		
			 
		

		
			 
		

		
			 
		

		 

		

			A-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]